MYGN
Myriad Genetics Inc
NASDAQ: MYGN · HEALTHCARE · DIAGNOSTICS & RESEARCH
$6.04
+3.25% today
Updated 2026-11-03
Market cap
$556.68M
P/E ratio
—
P/S ratio
0.69x
EPS (TTM)
$-1.18
Dividend yield
—
52W range
$3 – $9
Volume
2.4M
Myriad Genetics Inc (MYGN) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$6.04
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.7B | $0.7B | $0.8B | $0.8B | $0.8B | $0.9B | $1.0B | $1.0B | $1.1B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 8.16% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -14.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.